FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055557626> ?p ?o ?g. }

• W2055557626 abstract "In the last five years, countries have been faced with changing their malaria treatment policy to an artemisinin-based combination therapy (ACT), many with no national data on which to base their decision. This is particularly true for a number of West African countries, including Guinea, where these studies were performed. Two studies were conducted in 2004/2005 in programmes supported by Medecins Sans Frontieres, when chloroquine was still national policy, but artesunate (AS)/sulphadoxine-pyrimethamine (SP) had been used in refugee camps for two years.In Dabola (central Guinea), 220 children aged 6-59 months with falciparum malaria were randomized to receive either AS/amodiaquine (AQ) or AS/SP. In vivo efficacy was assessed following the 2003 World Health Organization guidelines. In a refugee camp in Laine (south of Guinea), where an in vivo study was not feasible due to the unstable context, a molecular genotyping study in 160 patients assessed the prevalence of mutations in the dihydrofolate reductase (dhfr) (codons 108, 51, 59) and dihydropteroate synthase (dhps) (codons 436, 437, 540) genes of Plasmodium falciparum, which have been associated with resistance to pyrimethamine and sulphadoxine, respectively.In Dabola, after 28 days of follow-up, Polymerase Chain Reaction (PCR)-adjusted failure rates were 1.0% (95%CI 0-5.3) for AS/AQ and 1.0% (95%CI 0-5.5) for AS/SP. In the refugee camp in Laine, the molecular genotyping study found three dhfr mutations in 85.6% (95%CI 79.2-90.7) patients and quintuple dhfr/dhps mutations in 9.6% (95%CI 5.2-15.9).Both AS/AQ and AS/SP are highly efficacious in Dabola, whereas there is molecular evidence of established SP resistance in Laine. This supports the choice of the national programme of Guinea to adopt AS/AQ as first line antimalarial treatment. The results highlight the difficulties faced by control programmes, which have gone through the upheaval of implementing ACTs, but cannot predict how long their therapeutic life will be, especially in countries which have chosen drugs also available as monotherapies." @default.
• W2055557626 created "2016-06-24" @default.
• W2055557626 creator A5034732857 @default.
• W2055557626 creator A5045991565 @default.
• W2055557626 creator A5075636609 @default.
• W2055557626 creator A5079487729 @default.
• W2055557626 creator A5007135099 @default.
• W2055557626 creator A5051493056 @default.
• W2055557626 date "2007-05-03" @default.
• W2055557626 modified "2023-10-13" @default.
• W2055557626 title "Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré" @default.
• W2055557626 cites W1958515160 @default.
• W2055557626 cites W1989290058 @default.
• W2055557626 cites W2060209469 @default.
• W2055557626 cites W2099198335 @default.
• W2055557626 cites W2108422125 @default.
• W2055557626 cites W2118248316 @default.
• W2055557626 cites W2118975746 @default.
• W2055557626 cites W2129494994 @default.
• W2055557626 cites W2132065545 @default.
• W2055557626 cites W2134055441 @default.
• W2055557626 cites W2145166645 @default.
• W2055557626 cites W2170936619 @default.
• W2055557626 cites W4211010162 @default.
• W2055557626 cites W4231557749 @default.
• W2055557626 cites W4300875451 @default.
• W2055557626 cites W4378637684 @default.
• W2055557626 doi "https://doi.org/10.1186/1475-2875-6-54" @default.
• W2055557626 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1868032" @default.
• W2055557626 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17477865" @default.
• W2055557626 hasPublicationYear "2007" @default.
• W2055557626 type Work @default.
• W2055557626 sameAs 2055557626 @default.
• W2055557626 citedByCount "34" @default.
• W2055557626 countsByYear W20555576262012 @default.
• W2055557626 countsByYear W20555576262013 @default.
• W2055557626 countsByYear W20555576262014 @default.
• W2055557626 countsByYear W20555576262015 @default.
• W2055557626 countsByYear W20555576262016 @default.
• W2055557626 countsByYear W20555576262020 @default.
• W2055557626 countsByYear W20555576262021 @default.
• W2055557626 countsByYear W20555576262022 @default.
• W2055557626 countsByYear W20555576262023 @default.
• W2055557626 crossrefType "journal-article" @default.
• W2055557626 hasAuthorship W2055557626A5007135099 @default.
• W2055557626 hasAuthorship W2055557626A5034732857 @default.
• W2055557626 hasAuthorship W2055557626A5045991565 @default.
• W2055557626 hasAuthorship W2055557626A5051493056 @default.
• W2055557626 hasAuthorship W2055557626A5075636609 @default.
• W2055557626 hasAuthorship W2055557626A5079487729 @default.
• W2055557626 hasBestOaLocation W20555576261 @default.
• W2055557626 hasConcept C104317684 @default.
• W2055557626 hasConcept C114851261 @default.
• W2055557626 hasConcept C135763542 @default.
• W2055557626 hasConcept C151730666 @default.
• W2055557626 hasConcept C159047783 @default.
• W2055557626 hasConcept C203014093 @default.
• W2055557626 hasConcept C2776120307 @default.
• W2055557626 hasConcept C2777035104 @default.
• W2055557626 hasConcept C2777234095 @default.
• W2055557626 hasConcept C2778048844 @default.
• W2055557626 hasConcept C2778059366 @default.
• W2055557626 hasConcept C2778301690 @default.
• W2055557626 hasConcept C2778371730 @default.
• W2055557626 hasConcept C2779343474 @default.
• W2055557626 hasConcept C2780866276 @default.
• W2055557626 hasConcept C31467283 @default.
• W2055557626 hasConcept C54355233 @default.
• W2055557626 hasConcept C71924100 @default.
• W2055557626 hasConcept C86803240 @default.
• W2055557626 hasConcept C89423630 @default.
• W2055557626 hasConcept C98274493 @default.
• W2055557626 hasConceptScore W2055557626C104317684 @default.
• W2055557626 hasConceptScore W2055557626C114851261 @default.
• W2055557626 hasConceptScore W2055557626C135763542 @default.
• W2055557626 hasConceptScore W2055557626C151730666 @default.
• W2055557626 hasConceptScore W2055557626C159047783 @default.
• W2055557626 hasConceptScore W2055557626C203014093 @default.
• W2055557626 hasConceptScore W2055557626C2776120307 @default.
• W2055557626 hasConceptScore W2055557626C2777035104 @default.
• W2055557626 hasConceptScore W2055557626C2777234095 @default.
• W2055557626 hasConceptScore W2055557626C2778048844 @default.
• W2055557626 hasConceptScore W2055557626C2778059366 @default.
• W2055557626 hasConceptScore W2055557626C2778301690 @default.
• W2055557626 hasConceptScore W2055557626C2778371730 @default.
• W2055557626 hasConceptScore W2055557626C2779343474 @default.
• W2055557626 hasConceptScore W2055557626C2780866276 @default.
• W2055557626 hasConceptScore W2055557626C31467283 @default.
• W2055557626 hasConceptScore W2055557626C54355233 @default.
• W2055557626 hasConceptScore W2055557626C71924100 @default.
• W2055557626 hasConceptScore W2055557626C86803240 @default.
• W2055557626 hasConceptScore W2055557626C89423630 @default.
• W2055557626 hasConceptScore W2055557626C98274493 @default.
• W2055557626 hasIssue "1" @default.
• W2055557626 hasLocation W20555576261 @default.
• W2055557626 hasLocation W20555576262 @default.
• W2055557626 hasLocation W20555576263 @default.
• W2055557626 hasLocation W20555576264 @default.
• W2055557626 hasLocation W20555576265 @default.
• W2055557626 hasOpenAccess W2055557626 @default.

• next